Prospects for the use of new generation of anti-tuberculosis drugs in treatment of drug-resistant tuberculosis

Cover Page
  • Authors: Pavlova M.V.1, Vinogradova T.I.1, Zabolotnykh N.V.1, Ershova E.S.1,2, Sapozhnikova N.V.1, Chernokhaeva I.V.1, Archakova L.I.1,3, Vitovskaya M.L.1, Dogonadze M.Z.1, Starshinova A.A.1, Grishko A.N.1, Yablonsky P.K.1,3
  • Affiliations:
    1. Saint Petersburg State Research Institute of Phthisiopulmonology
    2. State Establishment of the Khanty-Mansiysk Autonomous District – Yugra Khanty-Mansi Clinical Antitubercular Clinic
    3. Saint Petersburg State University
  • Issue: Vol 18, No 2 (2020)
  • Pages: 115-121
  • Section: Original articles
  • URL: https://journals.eco-vector.com/RCF/article/view/42400
  • DOI: https://doi.org/10.17816/RCF182115-121
  • Cite item
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


The aim of this work was an experimental and clinical study of increasing of the efficiency of therapy of respiratory tuberculosis with drug resistant pathogen by including a combination of anti-tuberculosis drugs of new generation – Bedaquiline (Bq) and Thioureidoiminomethylpyridi-nium perchlorate (perchlozone, Tpp) into treatment regimens. The presented results were obtained: in the experiment on a model of tuberculosis infection in 103 male C57black / 6 mice, reproduced by inserting into the lateral vein of the tail of a suspense of clinical strains of Mycobacterium tuberculosis with multi-drug resistance (MDR) and with various combinations of mutations in the genes; in the clinic – on the basis of examination and treatment of 148 patients with multidrug-resistant respiratory tuberculosis. It is shown that the application of the therapy schemes for multiple and broad drug resistant tuberculosis, containing Bq and Tpp in combination with drugs, selected taking into account the drug sensitivity of mycobacteria, allows to significantly reduce the periods of relief of symptoms of intoxication, regression of inflammatory changes, abacillation and achieving positive X-ray dynamics. Undesirable phenomena against the background of combined prescription of new generation drugs, as a rule, corresponded to light and moderate severity, and in frequency of development and expression did not differ from control groups of observation.


Full Text

Restricted Access

About the authors

Mariia V. Pavlova

Saint Petersburg State Research Institute of Phthisiopulmonology

Author for correspondence.
Email: mv@spbniif.ru

Russian Federation, Saint-Petersburg

Doctor of Medical Sciences, Professor, Leading Researcher

Tatiana I. Vinogradova

Saint Petersburg State Research Institute of Phthisiopulmonology

Email: vinogradova@spbniif.ru

Russian Federation, Saint-Petersburg

Doctor of Medical Sciences, Professor, Сhief Researcher

Natalia V. Zabolotnykh

Saint Petersburg State Research Institute of Phthisiopulmonology

Email: zabol-natal@yandex.ru

Russian Federation, Saint-Petersburg

Doctor of Medical Sciences, Leading Researcher

Elena S. Ershova

Saint Petersburg State Research Institute of Phthisiopulmonology; State Establishment of the Khanty-Mansiysk Autonomous District – Yugra Khanty-Mansi Clinical Antitubercular Clinic

Email: ele3897@mail.ru

Russian Federation, Saint-Petersburg; Khanty-Mansiysk

Graduate Student; Doctor-Phthisiatrician

Nadezhda V. Sapozhnikova

Saint Petersburg State Research Institute of Phthisiopulmonology

Email: n_sapozhnikova69@mail.ru

Russian Federation, Saint-Petersburg

Candidate of Medical Sciences, Senior Scientific Employee

Irina V. Chernokhaeva

Saint Petersburg State Research Institute of Phthisiopulmonology

Email: chernokhaev@mail.ru

Russian Federation, Saint-Petersburg

Candidate of Medical Sciences, Manager of Office of Therapy of Tuberculosis

Liudmila I. Archakova

Saint Petersburg State Research Institute of Phthisiopulmonology; Saint Petersburg State University

Email: spbniif_a@mail.ru

Russian Federation, Saint-Petersburg

Doctor of Medical Sciences, Deputy Chief Physician for a Medical Part; Associate Professor of Hospital Therapy of Medical Faculty

Mariia L. Vitovskaya

Saint Petersburg State Research Institute of Phthisiopulmonology

Email: mariavit72@mail.ru

Russian Federation, Saint-Petersburg

Candidate of Medical Sciences, Senior Research Associate

Marine Z. Dogonadze

Saint Petersburg State Research Institute of Phthisiopulmonology

Email: marine-md@mail.ru

Russian Federation, Saint-Petersburg

Candidate of Biology, Senior Research Associate

Anna A. Starshinova

Saint Petersburg State Research Institute of Phthisiopulmonology

Email: starshinova_777@mail.ru

Russian Federation, Saint-Petersburg

Doctor of Medical Sciences, Leading Researcher

Alevtina N. Grishko

Saint Petersburg State Research Institute of Phthisiopulmonology

Email: spbniif_all@mail.ru

Russian Federation, Saint-Petersburg

Doctor of Medical Sciences, Professor, Scientific Consultant

Petr K. Yablonsky

Saint Petersburg State Research Institute of Phthisiopulmonology; Saint Petersburg State University

Email: glhirurgb2@mail.ru

Russian Federation, Saint-Petersburg

Doctor of Medical Sciences, Professor, Director; Dean of Medical Faculty

References

  1. Айзиков Д.Л., Антонова Н.В., Сергиенко О.Б., и др. Опыт применения препаратов третьего ряда в условиях клинической практики // Туберкулез и социально значимые заболевания. – 2016. – № 5. – С. 7–12. [Isikov DL, Antonova NV, Sergienko OB, et al. Experience of the routine third-line antituberculosis drugs administration. Tuberculosis and socially significant diseases. 2016;(5):7-12. (In Russ.)]
  2. Беляева Е.Н. Особенности течения и эффективность терапии туберкулеза легких с широкой лекарственной устойчивостью возбудителя: Автореф. дис. … канд. мед. наук. – СПб., 2018. – 24 с. [Belyayeva EN. Osobennosti techeniya i effektivnost’ terapii tuberkuleza legkikh s shirokoy lekarstvennoy ustoychivost’yu vozbuditelya. [dissertation abstract] Saint Petersburg; 2018. 24 р. (In Russ.)]. Доступно по: https://search.rsl.ru/ru/record/01008708042. Ссылка активна на 14.03.2020.
  3. Борисов С.Е., Иванушкина Т.Н., Иванова Д.А., и др. Эффективность и безопасность включающих бедаквилин шестимесячных режимов химиотерапии у больных туберкулезом органов дыхания // Туберкулез и социально значимые заболевания. – 2015. – № 3. – С. 30–49. [Borisov SE, Ivanushkina TN, Ivanova DA, et al. Effectiveness and safety of the bedaquiline-containing six-month chemotherapy regimens in pulmonary tuberculosis patients. Tuberculosis and socially significant diseases. 2015;(3):30-49. (In Russ.)]
  4. Васильева И.А., Багдасарян Т.Р., Баласанянц Г.С., и др. Федеральные клинические рекомендации по диагностике и лечению туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью возбудителя. 3-е изд. – М.: ООО Нью-Терра, 2015. – 68 с. [Vasil’yeva IA, Bagdasaryan TR, Balasanyants GS, et al. Federal’nyye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstvennoy ustoychivost’yu vozbuditelya. Moscow: OOO N’yu-Terra; 2015. 68 р. (In Russ.)]
  5. ВОЗ. Информационный бюллетень. Ноябрь 2017. Ликвидировать туберкулез в эпоху устойчивого развития // Социальные аспекты здоровья населения. – 2017. – № 6. – С. 14. [VOZ. Informatsionnyy byulleten’. Noyabr’ 2017. Likvidirovat’ tuberkulez v epokhu ustoychivogo razvitiya. Social Aspects of Public Health. 2017;(6):14. (In Russ.)]
  6. Кондакова М.Н., Хабиров В.В., Жемков В.Ф., и др. Влияние бедаквилина на эффективность комплексной терапии туберкулеза органов дыхания // Туберкулез и болезни легких. – 2018. – Т. 96. – № 6. – С. 39–44. [Kondakova MN, Khabirov VV, Zhemkov VF, et al. Vliyaniye bedakvilina na effektivnost’ kompleksnoy terapii tuberkuleza organov dykhaniya. Tuberculosis and lung diseases. 2018;96(6):39-44. (In Russ.)]. https://doi.org/10.21292/2075-1230-2018-96-6-43.
  7. Нечаева О.В. Оценка последствий реформирования здравоохранения за последние 10 лет. Эпидемическая ситуация по туберкулезу // Туберкулез и болезни легких. – 2018. – Т. 96. – № 8. – С. 15–24. [Nechaeva OV. Assessing the impact of health reform over the past 10 years. Epidemic situation on tuberculosis. Tuberculosis and lung diseases. 2018;96(8):15-24. (In Russ.)]. https://doi.org/10.21292/2075-1230-2018-96-8-15-24.
  8. Николаева С.В. Опыт применения противотуберкулезного препарата перхлозон у больных туберкулезом с множественной лекарственной устойчивостью в Республике Бурятия // Туберкулез и болезни легких. – 2015. – № 10. – С. 64–68. [Nikolaeva SV. Opyt primeneniya protivotuberkuleznogo preparata perkhlozon u bol’nykh tuberkulezom s mnozhestvennoy lekarstvennoy ustoychivost’yu v Respublike Buryatiya. Tuberculosis and lung diseases. 2015;(10):64-68. (In Russ.)]
  9. Морозова Т.И., Отпущенникова О.Н., Докторова Н.П., Данилов А.Н. Опыт применения препарата бедаквилин в лечении больных туберкулезом легких с лекарственной устойчивостью возбудителя // Туберкулез и болезни легких. – 2016. – Т. 94. – № 2. – С. 29–35. [Morozova TI, Otpushchennikova ON, Doktorova NP, Danilov AN. Opyt primeneniya preparata bedakvilin v lechenii bol’nykh tuberkulezom legkikh s lekarstvennoy ustoychivost’yu vozbuditelya. Tuberculosis and lung diseases. 2016;94(2):29-35. (In Russ.)]
  10. Тихонов А.М., Буракова М.В., Ваниев Э.В., и др. Эффективность химиотерапии с применением бедаквилина у больных туберкулезом легких с лекарственной устойчивостью возбудителя // Туберкулез и болезни легких. – 2018. – Т. 96. – № 2. – С. 22–26. [Tikhonov AM, Burakova MV, Vaniyev EV, et al. Effektivnost’ khimioterapii s primeneniyem bedakvilina u bol’nykh tuberkulezom legkikh s lekarstvennoy ustoychivost’yu vozbuditelya. Tuberculosis and lung diseases. 2018;96(2):22-26. (In Russ.)]. https://doi.org/10.21292/2075-1230-2018-96-2-22-26.
  11. Чернохаева И.В. Эффективность применения тиоуреидоиминометилпиридиния перхлората в лечении туберкулеза со множественной лекарственной устойчивостью возбудителя. Автореф. дис. … канд. мед. наук. – СПб., 2017. – 24 с. [Chernohaeva IV. Effektivnost’ primeneniya tioureidoiminometilpiridiniya perkhlorata v lechenii tuberkuleza so mnozhestvennoy lekarstvennoy ustoychivost’yu vozbuditelya. [dissertation abstract] Saint Petersburg; 2018. 24 р. (In Russ.)]. Доступно по: https://search.rsl.ru/ru/record/01008711519. Ссылка активна на 14.03.2020.
  12. Фтизиатрия. Национальные клинические рекомендации / под ред. П.К. Яблонского. – М.: ГЭОТАР-Медиа, 2016. – 240 с. [Ftiziatriya. Natsional’nyye klinicheskiye rekomendatsii. Ed. by P.K. Yablonskiy. Moscow: GEOTAR-Media; 2016. 240 р. (In Russ.)]
  13. Яблонский П.К., Виноградова Т.И., Левашев Ю.Н., и др. Доклинические и клинические исследования нового противотуберкулезного препарата «Перхлозон» // Клиническая микробиология и антимикробная химиотерапия. – 2016. – Т. 18. – № 1. – С. 42–48. [Yablonskiy PK, Vinogradova TI, Levashev YuN, et al. Nonclinical and clinical studies of the new anti-tuberculosis drug «Perchlozone». Clinical microbiology and antimicrobial chemotherapy. 2016;18(1):42-48. (In Russ.)]
  14. Matteelli A, Rendon A, Tiberi S, et al. Tuberculosis elimination: where are we now? Eur Respir Rev. 2018;27(148): 180035. https://doi.org/10.1183/16000617.0035-2018.

Statistics

Views

Abstract - 72

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2020 Pavlova M.V., Vinogradova T.I., Zabolotnykh N.V., Ershova E.S., Sapozhnikova N.V., Chernokhaeva I.V., Archakova L.I., Vitovskaya M.L., Dogonadze M.Z., Starshinova A.A., Grishko A.N., Yablonsky P.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies